Does Scale-Out Technology Offer Truly Flexible Biologic Production?

De-risking drug production at larger scales and later phases with modular bioreactor systems

Read insights from one of our expert scientists from AGC Biologics' Copenhagen site as he provides an in-depth explanation on how using a flexible scale-out manufacturing strategy with multiple mirrored, single-use bioreactors helps drug developers reduce risk, cost, and time-to-market compared to traditional large-scale methods.

Key takeaways

• Scale-out systems allow for highly flexible production based on evolving supply needs

• How this method simplifies comparability and PPQ/validation strategies

• Why this eases the path to regulatory approval

• How combining scale-out systems with perfusion technology can maximize output